Health utilities and parental quality of life effects for three rare conditions tested in newborns.
Cost-effectiveness
Family effects
Health disutility
Health utilities
Krabbe
Newborn screening
Phenylketonuria
Pompe
Spillover
Time trade-off
Journal
Journal of patient-reported outcomes
ISSN: 2509-8020
Titre abrégé: J Patient Rep Outcomes
Pays: Germany
ID NLM: 101722688
Informations de publication
Date de publication:
22 Jan 2019
22 Jan 2019
Historique:
received:
20
09
2018
accepted:
04
01
2019
entrez:
24
1
2019
pubmed:
24
1
2019
medline:
24
1
2019
Statut:
epublish
Résumé
Measurement of health utilities is required for economic evaluations. Few studies have evaluated health utilities for rare conditions; even fewer have incorporated disutility that may be experienced by caregivers. This study aimed to (1) estimate health utilities for three rare conditions currently recommended for newborn screening at the state or federal level, and (2) estimate the disutility, or spillover, experienced by parents of patients diagnosed with a rare, heritable disorder. A stated-preference survey using a time trade-off approach elicited health utilities for Krabbe disease, phenylketonuria, and Pompe disease at varying stages (mild, moderate, severe) and onset of disease symptoms (infancy, childhood, and adulthood). We recruited respondents from a nationally representative community sample (n = 862). Respondents valued disease specific health states in three consecutive question frames: (1) adult health state (> = 18 years of age), (2) child health state (< 18 years of age), and (3) as a parent of a child with a condition (parent spillover state). Corresponding mean utilities were calculated for plausible disease states in adulthood and childhood. Mean disutility was estimated for parental spillover. Predictors of utilities were evaluated using a negative binomial regression model. More severe conditions and infant health states received lower estimated utility and greater estimated disutility among parents. Conditions with the lowest estimated health utilities were severe infantile Pompe disease (0.40, CI: 0.34-0.46) and infantile Krabbe disease (0.37, CI: 0.32-0.43). Disutility was evident for all conditions evaluated (range: 0.07-0.19). Rare childhood conditions are associated with substantial estimated losses in quality of life. Evidence of disutility among parents further warrants the inclusion of spillover effects in cost-effectiveness analyses. Continued research is needed to assess and measure the effects of childhood disease from a family perspective.
Sections du résumé
BACKGROUND
BACKGROUND
Measurement of health utilities is required for economic evaluations. Few studies have evaluated health utilities for rare conditions; even fewer have incorporated disutility that may be experienced by caregivers. This study aimed to (1) estimate health utilities for three rare conditions currently recommended for newborn screening at the state or federal level, and (2) estimate the disutility, or spillover, experienced by parents of patients diagnosed with a rare, heritable disorder.
METHODS
METHODS
A stated-preference survey using a time trade-off approach elicited health utilities for Krabbe disease, phenylketonuria, and Pompe disease at varying stages (mild, moderate, severe) and onset of disease symptoms (infancy, childhood, and adulthood). We recruited respondents from a nationally representative community sample (n = 862). Respondents valued disease specific health states in three consecutive question frames: (1) adult health state (> = 18 years of age), (2) child health state (< 18 years of age), and (3) as a parent of a child with a condition (parent spillover state). Corresponding mean utilities were calculated for plausible disease states in adulthood and childhood. Mean disutility was estimated for parental spillover. Predictors of utilities were evaluated using a negative binomial regression model.
RESULTS
RESULTS
More severe conditions and infant health states received lower estimated utility and greater estimated disutility among parents. Conditions with the lowest estimated health utilities were severe infantile Pompe disease (0.40, CI: 0.34-0.46) and infantile Krabbe disease (0.37, CI: 0.32-0.43). Disutility was evident for all conditions evaluated (range: 0.07-0.19).
CONCLUSIONS
CONCLUSIONS
Rare childhood conditions are associated with substantial estimated losses in quality of life. Evidence of disutility among parents further warrants the inclusion of spillover effects in cost-effectiveness analyses. Continued research is needed to assess and measure the effects of childhood disease from a family perspective.
Identifiants
pubmed: 30671727
doi: 10.1186/s41687-019-0093-6
pii: 10.1186/s41687-019-0093-6
pmc: PMC6342747
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4Subventions
Organisme : Agency for Healthcare Research and Quality
ID : R01 HS020644
Références
Arch Pediatr Adolesc Med. 2000 Jan;154(1):43-8
pubmed: 10632249
Annu Rev Public Health. 2000;21:587-611
pubmed: 10884966
J Pediatr. 2002 May;140(5):516-21
pubmed: 12032515
J Pediatr. 2002 Oct;141(4):524-31
pubmed: 12378192
Qual Life Res. 2003 Sep;12(6):599-607
pubmed: 14516169
Pediatrics. 2004 Feb;113(2):283-90
pubmed: 14754939
Neurology. 2004 Nov 9;63(9):1688-92
pubmed: 15534256
J Gen Intern Med. 2005 Feb;20(2):175-84
pubmed: 15836552
Qual Life Res. 2006 Aug;15(6):1005-21
pubmed: 16900281
J Inherit Metab Dis. 2007 Feb;30(1):29-34
pubmed: 17160615
Pharmacoeconomics. 2007;25(9):713-26
pubmed: 17803331
Health Qual Life Outcomes. 2008 Mar 26;6:25
pubmed: 18366761
Arch Pediatr Adolesc Med. 2008 Sep;162(9):870-6
pubmed: 18762606
Matern Child Health J. 2010 Mar;14(2):155-63
pubmed: 19034635
Pediatrics. 2010 Feb;125(2):e286-94
pubmed: 20123779
Expert Rev Pharmacoecon Outcomes Res. 2010 Jun;10(3):293-308
pubmed: 20545594
Genet Med. 2010 Sep;12(9):539-43
pubmed: 20601893
Med Decis Making. 2011 Mar-Apr;31(2):292-8
pubmed: 20671212
Value Health. 2011 Jan;14(1):135-43
pubmed: 21211495
J Inherit Metab Dis. 2011 Oct;34(5):1045-52
pubmed: 21499718
Qual Life Res. 2012 Jun;21(5):849-61
pubmed: 21858419
Pharmacoeconomics. 2013 Jun;31(6):489-500
pubmed: 23572441
Genet Med. 2014 Feb;16(2):183-7
pubmed: 23907646
Orphanet J Rare Dis. 2014 May 16;9:75
pubmed: 24884717
Med Decis Making. 2015 Jan;35(1):81-93
pubmed: 25057048
Qual Life Res. 2015 Apr;24(4):837-44
pubmed: 25342117
Natl Vital Stat Rep. 2014 Nov;63(7):1-63
pubmed: 25383611
Healthcare (Basel). 2015;3(4):1133-57
pubmed: 26702401
JAMA. 2016 Sep 13;316(10):1093-103
pubmed: 27623463
Med Decis Making. 2017 Apr;37(3):314-326
pubmed: 27694286
Eur Respir J. 1997 Oct;10(10):2285-94
pubmed: 9387955